News – Page 3 – Alligator Bioscience

2023-07-13

Regulatory

Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-07-11

Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...

2023-07-05

Alligator Bioscience AB (publ) today announces that Anette Sundstedt, PhD, Principal Scientist at Alligator, has been appointed as employee ...

2023-06-302023-07-03

BioStock interview with Alligator CMO, Sumeet Ambarkhane. Following the second round of interim results from OPTIMIZE-1, the phase 2 trial w ...

2023-06-30

Regulatory

During June 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the ...

2023-06-26

Regulatory

Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...

2023-06-13

June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) ...

2023-06-082023-06-08

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-06-05

Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...